HUNTSVILLE — John Schmitt has been named CEO of iXpressGenes, a biotechnology company transforming trauma care. Schmitt is a cofounder of iXG, an associate company at HudsonAlpha Institute for Biotechnology.
The company also announced the nationwide launch of its Trauma Autoimmune Indicator test, available by the second quarter of next year.
This cutting-edge advancement represents a paradigm shift in trauma detection and prevention, empowering healthcare providers to identify trauma-induced diseases like PTSD before symptoms emerge.
As a 20-year Army veteran, Schmitt understands firsthand the devastating impact trauma can have on mental and physical health. In addition to being a combat leader, he served in a variety of capacities from assistant professor at the United States Military Academy to leadership roles in science and technology as well as major defense acquisition programs. Schmitt received his master’s in microbiology and immunology from Vanderbilt University School of Medicine.
“I’m honored to lead this world-class team and grateful for the opportunity to combine scientific passions and leadership experiences to continue to serve in a meaningful way,” said Schmitt. “The TAI test is a game-changing evolution on the path of precision medicine, giving providers the tools to detect trauma-induced diseases like PTSD early to minimize human suffering and help relieve overburdened mental health systems.
“This launch marks a critical step in fundamentally changing the paradigm faced by survivors of trauma from receiving reactive to preventative care.”
iXG is honored to have received support from influential congressional leaders, including members of the Senate and House Veterans Affairs Committees. This backing underscores the critical role iXG plays in addressing the PTSD crisis within the veteran community.
Congressional leaders have acknowledged the importance of fostering innovation in preventative care, reinforcing the importance of providing transformative solutions for veterans and active-duty service members alike.
“We are so proud of the support we’ve received from our congressional leaders,” said Schmitt, “Their commitment strengthens our ability to make a meaningful impact in the lives of our veterans and aligns with bipartisan efforts to advance preventative trauma care.”
With federal leaders recognizing the urgency of addressing PTSD through innovative solutions, iXG remains steadfast in its work.
“iXG is committed to continuing its collaboration with federal partners to achieve transformative outcomes,” Schmitt said.
iXG has uncovered that prolonged stress and trauma can lead to differentiated inflammation and autoimmune responses in the body. This inflammation can result in severe trauma-induced diseases including PTSD, autoimmune diseases, chronic pain syndromes, cardiovascular diseases, and more. Using its revolutionary TAI test, iXG can detect specific biomarkers that indicate developing trauma-related disease before symptoms ever manifest, enabling prevention and early intervention.
iXG is committed to equipping healthcare providers with the tools they need to make a lasting difference. By combining groundbreaking technology with visionary leadership, iXG is driving a shift from reactive treatment to proactive prevention — empowering providers to take a more precise, impactful approach to trauma care.
iXG’s TAI test integrates effortlessly into existing clinical workflows, providing:
- A Baseline for Health: Use TAI screening to establish a starting point for treatment and monitor progress over time
- Early Intervention Opportunities: Prevent costly treatments by addressing trauma-related conditions before symptoms worsen
- Objective, Actionable Data: Move beyond self-reporting with measurable insights that guide precise care
- Relapse Prevention: Detect early signs of recurrence to intervene promptly and help prevent setbacks.
Don’t miss out! Subscribe to our email newsletter to have all our smart stories delivered to your inbox.
